-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the aging of the population, changing life>
.
It is worth mentioning that since there is still a huge unmet demand in the ophthalmology market, domestic and foreign pharmaceutical companies are also vying to lay out the field of eye disease treatment
.
Recently, Lineage Cell Therapeutics announced that it has signed an exclusive global cooperation and licensing agreement with its subsidiary Cell Cure Neurosciences and Roche subsidiary Genentech to jointly develop and commercialize retinal pigment epithelial (RPE) cell therapy to treat eye diseases, including advanced disease.
Sexual age-related macular degeneration (AMD) is accompanied by geographic atrophy (GA)
.
According to the terms of the cooperation agreement, Genentech will be responsible for the further clinical development and commercialization of Lineage's OpRegen® project, and Lineage will complete the work related to the ongoing clinical research (registration has been completed) and perform certain manufacturing tasks
.
At that time, Genentech will pay Lineage an upfront payment of US$50 million, and Lineage will be eligible for additional development, approval and sales milestone payments of up to US$620 million, as well as double-digit tiered royalties
.
Industry analysts believe that as the ophthalmic drug market becomes more and more promising, relevant companies will accelerate market expansion
.
In addition to increasing R&D investment and exploring breakthrough new ophthalmic drugs and therapies, cooperation between pharmaceutical companies in this field will also be normalized
.
Of course, in addition to multinational companies, a large number of local pharmaceutical companies are actually making arrangements in this field by increasing R&D investment and introduction
.
At present, more and more local enterprises have begun to usher in gains
.
For example, on November 9, Huahai Pharmaceutical issued an announcement stating that its subsidiary, Huabo Biotechnology, had recently received a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (hereinafter referred to as " HB002.
1M”) project "Notice of Approval of Supplementary Application for Drug Clinical Trial"
.
In August of this year, Huabo Biotechnology submitted a supplementary application for clinical trials of new formulation specifications to the State Food and Drug Administration and was accepted; recently, the State Food and Drug Administration agreed to increase the specifications of the drug and conduct clinical trials
.
In addition, some time ago, Hengrui Medicine also announced that SHR8058 eye drops for the treatment of meibomian gland dysfunction-related dry eye disease in a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) has achieved the primary study endpoint.
The pre-established superiority standards of the plan will be submitted to the CDE for pre-market communication applications in the near future
.
It is worth noting that in addition to SHR8058 eye drops, the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, have also been approved for marketing, becoming the first imitation of the product
.
From an overall point of view, the analysis believes that with the intensification of aging, changes in living habits, and faster pace of life, the number of patients with various eye diseases will continue to grow, and the market will continue to expand
.
In this context, domestic companies must continue to strengthen innovation and continue to develop breakthrough new ophthalmic drugs and therapies in order to compete with foreign companies and further meet the unmet clinical needs of the domestic ophthalmology market
.
.
It is worth mentioning that since there is still a huge unmet demand in the ophthalmology market, domestic and foreign pharmaceutical companies are also vying to lay out the field of eye disease treatment
.
Recently, Lineage Cell Therapeutics announced that it has signed an exclusive global cooperation and licensing agreement with its subsidiary Cell Cure Neurosciences and Roche subsidiary Genentech to jointly develop and commercialize retinal pigment epithelial (RPE) cell therapy to treat eye diseases, including advanced disease.
Sexual age-related macular degeneration (AMD) is accompanied by geographic atrophy (GA)
.
According to the terms of the cooperation agreement, Genentech will be responsible for the further clinical development and commercialization of Lineage's OpRegen® project, and Lineage will complete the work related to the ongoing clinical research (registration has been completed) and perform certain manufacturing tasks
.
At that time, Genentech will pay Lineage an upfront payment of US$50 million, and Lineage will be eligible for additional development, approval and sales milestone payments of up to US$620 million, as well as double-digit tiered royalties
.
Industry analysts believe that as the ophthalmic drug market becomes more and more promising, relevant companies will accelerate market expansion
.
In addition to increasing R&D investment and exploring breakthrough new ophthalmic drugs and therapies, cooperation between pharmaceutical companies in this field will also be normalized
.
Of course, in addition to multinational companies, a large number of local pharmaceutical companies are actually making arrangements in this field by increasing R&D investment and introduction
.
At present, more and more local enterprises have begun to usher in gains
.
For example, on November 9, Huahai Pharmaceutical issued an announcement stating that its subsidiary, Huabo Biotechnology, had recently received a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (hereinafter referred to as " HB002.
1M”) project "Notice of Approval of Supplementary Application for Drug Clinical Trial"
.
In August of this year, Huabo Biotechnology submitted a supplementary application for clinical trials of new formulation specifications to the State Food and Drug Administration and was accepted; recently, the State Food and Drug Administration agreed to increase the specifications of the drug and conduct clinical trials
.
In addition, some time ago, Hengrui Medicine also announced that SHR8058 eye drops for the treatment of meibomian gland dysfunction-related dry eye disease in a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) has achieved the primary study endpoint.
The pre-established superiority standards of the plan will be submitted to the CDE for pre-market communication applications in the near future
.
It is worth noting that in addition to SHR8058 eye drops, the tafluprost eye drops declared by Chengdu Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of Hengrui Pharmaceuticals, have also been approved for marketing, becoming the first imitation of the product
.
From an overall point of view, the analysis believes that with the intensification of aging, changes in living habits, and faster pace of life, the number of patients with various eye diseases will continue to grow, and the market will continue to expand
.
In this context, domestic companies must continue to strengthen innovation and continue to develop breakthrough new ophthalmic drugs and therapies in order to compete with foreign companies and further meet the unmet clinical needs of the domestic ophthalmology market
.
